The anticoagulant drug Eliquis, a product of Bristol-Myers Squibb and Pfizer, is slated to become available through Mark Cuban's Cost Plus Drug Company.

Several prominent companies, including Cigna, Pfizer, and United Rentals, declared their latest dividend payouts to shareholders, with some announcing regular distributions and one a special dividend.

Pfizer has announced that its top strategy executive will be leaving the company.

CICC has begun its coverage of pharmaceutical giant Pfizer Inc. (PFE) with an 'Outperform' rating, signaling a positive outlook for the company's stock.

Romanian Health and Finance Ministers held an exploratory meeting with Pfizer in Washington D.C. to discuss converting the country's COVID-19 vaccine debt into innovative medicines.

Former Romanian Health Minister Alexandru Rafila has explained his inability to make a key decision regarding Pfizer vaccine contracts during his time in office, citing three specific reasons. His statements have drawn reproaches towards former Prime Minister Nicolae Ciucă and contradictions from former minister Vlad Voiculescu.

UBS has revised its outlook for the pharmaceutical sector and increased its price target for Pfizer (PFE).

Romania's Health Minister Alexandru Rogobete announced a visit to Washington this week to meet with representatives from the World Bank and major US health companies, including Pfizer, following Romania's loss in a lawsuit concerning COVID-19 vaccines.

Bank of America has raised its price target for Teva Pharmaceutical (TEVA) stock to $42.

Pfizer's stock experienced a significant tumble on Tuesday, with reasons for the decline being analyzed.

An analysis argues that AbbVie's dividend strategy offers more sustainable growth compared to Pfizer's, despite a potentially lower payout.

Poland and Romania have reportedly been ordered to honor their existing vaccine supply agreements with pharmaceutical giant Pfizer, indicating a resolution or directive regarding past contractual disputes.

Poland is facing a significant financial penalty from Pfizer due to a dispute over unused COVID-19 vaccine orders. An analysis is underway to determine accountability and whether the financial consequences could have been avoided under the EU agreement.

A Brussels court has ruled that Poland must pay an estimated €5.6 billion (6 billion PLN) for COVID-19 vaccines from Pfizer, which are now likely to be disposed of, following a broken supply contract. The Polish government has criticized the previous administration's handling of the agreement.

A Belgian court has ordered Poland to pay Pfizer €1.3 billion (5.6 billion PLN) for uncollected COVID-19 vaccines. The Polish government has stated its intention to appeal the decision and pursue all legal means to defend its interests.

Alexandru Rafila, former PSD Health Minister during the pandemic, defended the decision to cancel 29 million COVID vaccine doses after Romania lost a lawsuit with Pfizer, stating it was a 'correct decision' following numerous negotiation rounds.

Pfizer (PFE) has been highlighted as one of the top 15 large-cap stocks offering the highest dividends.

Income investors are reportedly confronting a difficult reality regarding the safety of Pfizer's dividend payouts.

Analysts project Pfizer's stock could hit $36 by year-end, citing a 2-to-1 payoff potential from a key prostate cancer trial.

Pfizer's stock is exhibiting a market behavior that has not been observed since 2022, drawing attention from investors.

Pfizer and Valneva's Lyme disease vaccine trial showed strong efficacy but reportedly missed a specific mark, complicating its path to regulatory approval from the FDA, as further reports confirm.

Ce sérum protège à plus de 70% contre cette maladie transmise par des tics.

Pfizer Inc. (PFE) is being highlighted as one of Goldman Sachs' top healthcare stock picks, suggesting strong investment potential.

The 4th cycle of Pfizer's Start4Health25 program, implemented by its Digital Innovation Center (CDI) in Thessaloniki, concluded with an awards ceremony for two distinguished startups.

China approves Pfizer GLP-1 drug for weight management  Reuters

Priovant, a company backed by Pfizer, has received FDA priority review for its lead asset, indicating a fast-tracked evaluation process for a new drug.

Novavax has projected a 2026 revenue target of $230 million to $270 million, supported by a new partnership with Pfizer and a cost reduction strategy.

Pfizer announced that its drug Braftovi has received full approval from the FDA for the treatment of colorectal cancer.

Pfizer in diabetes drug deal with Sciwind Biosciences  Reuters

Pfizer Inc (PFE) has announced positive results from its BREAKWATER trial, marking a significant development for the pharmaceutical company.

A New Jersey woman is among over 2,000 individuals suing Pfizer, alleging complications from a birth control product she believed was safe.

Pfizer Inc. (PFE) stock is identified as one of the best and safest investment options for beginner investors.

An investment analysis article explores whether investors should consider an alternative pharmaceutical stock over Pfizer, evaluating potential opportunities and risks in the pharma sector. The piece offers guidance on portfolio decisions within the industry.

Pfizer is exploring a monthly weight loss shot that could potentially disrupt the current GLP-1 market, currently dominated by Lilly and Novo Nordisk.

Andrew Baum, Pfizer's Strategy and Innovation Officer, is reportedly leaving the pharmaceutical company, according to an analyst note.

Romania is reportedly seeking to convert its EUR 600 million debt to Pfizer into a supply of medicines, aiming to address healthcare needs.

Former Romanian Minister of Health Alexandru Rafila claims that in 2023, he submitted a proposal from the European Commission and Pfizer to then-Prime Minister Nicolae Ciucă regarding a reduction in vaccine doses for Romania, but received no response despite following up twice.

The Romanian government is in discussions with Pfizer to convert a €600 million payment owed to the company into innovative medicines.

An earnings preview details what to expect from Pfizer's upcoming financial report, providing insights into the pharmaceutical giant's performance.

Romanian Health Minister Alexandru Rogobete is in Washington for discussions with Pfizer and other pharmaceutical giants, as well as World Bank representatives, to address financial losses related to COVID-19 vaccines.

Poland reportedly has a 70-year supply of vaccines, and the Deputy Health Minister, Katarzyna Kacperczyk, commented on a court ruling concerning Pfizer. She indicated that the verdict necessitates accepting COVID-19 vaccines, despite the country's substantial existing stock.

A new prediction suggests that investors who purchase Pfizer stock today will regret not doing so in five years, indicating a positive long-term outlook for the pharmaceutical company.

Romania's Health Minister, Alexandru Rogobete, addressed the country's lost lawsuit against Pfizer, stating that the €600 million debt will be paid. He expressed confidence in negotiating with Pfizer to receive other products in exchange for the sum, noting that approximately 3.5 million vaccine doses were destroyed.

A Brussels court ruled that Poland must accept COVID-19 vaccines from Pfizer and pay €1.32 billion, an unprecedented decision that will result in 64 million doses needing to be destroyed.

Poland's dispute with Pfizer regarding unreceived COVID-19 vaccines could cost the national budget nearly 6 billion PLN, raising questions about accountability and the broader context of the pandemic agreement.

Polish Minister Marcin Kierwiński announced that the government will appeal a Brussels court ruling concerning undelivered Pfizer vaccines, stating their disagreement with the decision.

The Polish government will appeal a Brussels court decision that ordered the country to pay Pfizer 5.6 billion PLN for uncollected COVID-19 vaccines.

Pfizer and BioNTech have halted a U.S. COVID-19 vaccine study, citing difficulties in recruitment and weak demand for the shots.

Pharmaceutical giant Pfizer is reportedly planning to close its research site located in South San Francisco.

Jim Cramer has indicated that he requires a better understanding of Pfizer's product flow before making a definitive investment recommendation.

An article provides an analysis on whether Pfizer stock is a good investment following a recent positive development for the company.

Pfizer and Valneva have reported strong efficacy data from their joint Lyme vaccine trial, indicating positive progress in its development.

A recent study has shown that Pfizer's Lyme disease vaccine did not meet its efficacy targets, complicating its path toward regulatory approval.

Pfizer’s Lyme Vaccine Misses Mark in Study, Complicating Quest for Approval  WSJ

Pharmaceutical giants Pfizer and French partner Valneva announced plans to seek regulatory approval for their Lyme disease vaccine following successful late-stage trial results.

The company said more ‌than 90% of patients started atirmociclib ​within three months of stopping their previous cancer medicine

The CEO of IP Group provided insights into the company's projected highlights for 2025, including anticipated net asset value uplift, Pfizer royalties, and capital allocation strategies.

An article details a covered call strategy designed to trade high-yielding Pfizer stock, aiming to generate extra income for investors.

Pfizer has received approval in China for its obesity drug, positioning itself in the market as generic alternatives are anticipated.

An investor shares a reason why they would happily buy Pfizer (PFE) stock and never sell, offering a long-term bullish perspective.

RBC Capital initiates coverage on Pfizer (PFE) with a $25 target, highlighting structural revenue headwinds.

An analysis suggests that Pfizer, a dividend giant, could provide significant income for healthcare allocations.

An analysis explores whether Pfizer stock is an underrated investment opportunity within the healthcare sector.

Analysts are providing their outlook on where Pfizer Inc. (PFE) is headed, offering insights into its future performance.

The Siptu trade union is seeking urgent discussions with Pfizer after the pharmaceutical company confirmed a threat to 102 jobs, following an evaluation of its manufacturing network due to an expected decline in demand.

Pfizer's GLP-1 weight loss drug is now available for pre-order in China, marking its entry into the country's market.

A new development has emerged in the legal dispute over a Belgian court's ruling ordering Poland to pay nearly 6 billion PLN for undelivered COVID-19 vaccines from Pfizer. Poland may now have a new line of defense concerning a potential 'legal defect' in the preparations.

Pfizer and Astellas have received FDA priority review for their bladder cancer treatment, Padcev, when used in combination with Merck's Keytruda, signaling a potential expedited approval process for the therapy.

An article provides an outlook on where Pfizer's stock might be positioned in the next three years, offering insights into its potential future performance.

Zacharias Ragousis is stepping down as CEO of Pfizer Greece, Cyprus & Malta after nearly 40 years, with Vassilis Tzinieris taking over as the new president.

Romanian Prime Minister Marcel Ciolacu stated in a press conference that the Romanian government was aware it risked losing the lawsuit with Pfizer but attempted to "stall for time." This admission comes amidst the ongoing Pfizer scandal.

Documents obtained by Digi24 reveal that the Romanian Ministry of Health was aware of key decisions regarding the Pfizer contract in 2023 and attempted to shift responsibility.

Elon Musk has supported claims that COVID-19 vaccines caused thousands of deaths in Germany, referencing concerns raised by Dr. Helmut Sterz, a former Pfizer toxicologist, regarding the rapid development and testing of Pfizer's Comirnaty mRNA vaccine.

Romania's Premier Ilie Bolojan announced that the Health and Finance ministers will travel to the United States next week to negotiate with Pfizer, following a lost lawsuit concerning COVID-19 vaccine procurement.

Romania's President Nicușor Dan stated that contracts with Pfizer should be made public following the country's lost lawsuit against the pharmaceutical company, citing an "information war."

Romania's Finance Minister Alexandru Nazare denied signing a 2021 memorandum to prevent payments for unreceived Pfizer vaccines, while former Health Ministers Vlad Voiculescu and Alexandru Rafila have begun accusing each other regarding the ongoing Pfizer lawsuit over COVID-19 vaccine acquisition.

Poland is facing a significant penalty due to a dispute with Pfizer concerning millions of unused COVID-19 vaccine doses, prompting an analysis of the EU agreement and government decisions.

Romania's Health Minister, Alexandru Rogobete, has proposed settling the country's nearly 3.4 billion lei debt to Pfizer for COVID-19 vaccines by receiving other pharmaceutical products, and is now asking for public opinion on this negotiation.

Pfizer's RSV vaccine is now being offered to an additional three million older adults across England as part of an expanded public health initiative.

A Brussels court has ordered Romania to pay over 600 million euros for unclaimed COVID-19 vaccines from Pfizer, leading to a political blame game over mismanagement.

Fostul ministru al Sănătății, actual deputat PSD, Alexandru Rafila, a susținut că decizia de a nu mai achiziționa 29 de milioane de doze de vaccin anti-COVID contractate în 2021 a fost una „corectă”…

Investors are reportedly bearish on Pfizer (PFE) as its substantial dividend fails to mask underlying concerns about the company's growth prospects.

Pfizer's (PFE) shares have increased even after Jim Cramer advised investors to "pass" on the stock.

Guggenheim analysts have identified a favorable risk-reward scenario for Pfizer's stock (PFE) as the company approaches the release of its Phase 3 clinical trial data.

Pfizer Inc. has announced positive topline results from its Phase 3 TALAPRO-3 study of TALZENNA®, indicating successful outcomes for the drug.

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial WSJ

A study on Pfizer's Lyme vaccine reportedly missed its mark, potentially complicating the drug's path to regulatory approval.

Pfizer and Valneva announced their Lyme disease vaccine demonstrated over 70% efficacy in trials, though it missed a specific goal, potentially complicating its regulatory approval process.

Huons, a South Korean pharmaceutical company specializing in ophthalmic and injectable medicines, said Thursday it has received Investigational New Drug approval from the Ministry of Food and Drug…

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study  Reuters

Argus adopts a bullish stance on Pfizer, emphasizing the company's GLP-1 and oncology pipeline developments.

Pfizer Inc. and Astellas Pharma have announced positive results from their Phase 3 EV-304 clinical trial for the drug PADCEVTM.

An analysis evaluates whether Pfizer's stock is underperforming compared to the broader healthcare sector.

Pfizer has finalized a deal worth $495 million to secure the rights for an obesity drug in China, expanding its pharmaceutical presence in the region.

Moderna is facing a lawsuit alleging that its COVID-19 vaccine violates a patent linked to the Pfizer/BioNTech shot.